Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪2.28 B‬USD
‪−184.68 M‬USD
‪77.43 M‬USD
‪54.50 M‬
Beta (1Y)

About Rhythm Pharmaceuticals, Inc.

David P. Meeker
Employees (FY)
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of RYTM is 37.24 USD — it has decreased by 0.34% in the past 24 hours. Watch Rhythm Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Rhythm Pharmaceuticals, Inc. stocks are traded under the ticker RYTM.
RYTM stock has fallen by 5.59% compared to the previous week, the month change is a 8.20% fall, over the last year Rhythm Pharmaceuticals, Inc. has showed a 126.82% increase.
We've gathered analysts' opinions on Rhythm Pharmaceuticals, Inc. future price: according to them, RYTM price has a max estimate of 79.00 USD and a min estimate of 42.00 USD. Watch RYTM chart and read a more detailed Rhythm Pharmaceuticals, Inc. stock forecast: see what analysts think of Rhythm Pharmaceuticals, Inc. and suggest that you do with its stocks.
RYTM reached its all-time high on Feb 12, 2024 with the price of 52.57 USD, and its all-time low was 3.04 USD and was reached on May 20, 2022. View more price dynamics on RYTM chart.
See other stocks reaching their highest and lowest prices.
RYTM stock is 3.15% volatile and has beta coefficient of 2.10. Track Rhythm Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Rhythm Pharmaceuticals, Inc. there?
Today Rhythm Pharmaceuticals, Inc. has the market capitalization of ‪2.28 B‬, it has increased by 11.19% over the last week.
Yes, you can track Rhythm Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Rhythm Pharmaceuticals, Inc. is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
RYTM earnings for the last quarter are −2.35 USD per share, whereas the estimation was −2.36 USD resulting in a 0.27% surprise. The estimated earnings for the next quarter are −0.71 USD per share. See more details about Rhythm Pharmaceuticals, Inc. earnings.
Rhythm Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪25.97 M‬ USD despite the estimated figure of ‪26.90 M‬ USD. In the next quarter revenue is expected to reach ‪29.29 M‬ USD.
RYTM net income for the last quarter is ‪−141.37 M‬ USD, while the quarter before that showed ‪−41.62 M‬ USD of net income which accounts for −239.67% change. Track more Rhythm Pharmaceuticals, Inc. financial stats to get the full picture.
No, RYTM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 24, 2024, the company has 226.00 employees. See our rating of the largest employees — is Rhythm Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Rhythm Pharmaceuticals, Inc. EBITDA is ‪−269.80 M‬ USD, and current EBITDA margin is −235.83%. See more stats in Rhythm Pharmaceuticals, Inc. financial statements.
Like other stocks, RYTM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Rhythm Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Rhythm Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Rhythm Pharmaceuticals, Inc. stock shows the buy signal. See more of Rhythm Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.